Open AccessNovel combination of serum microRNA for detecting breast cancer in the early stage
Author(s) -
Shimomura Akihiko,
Shiino Sho,
Kawauchi Junpei,
Takizawa Satoko,
Sakamoto Hiromi,
Matsuzaki Juntaro,
Ono Makiko,
Takeshita Fumitaka,
Niida Shumpei,
Shimizu Chikako,
Fujiwara Yasuhiro,
Kinoshita Takayuki,
Tamura Kenji,
Ochiya Takahiro
Publication year - 2016
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12880
Subject(s) - breast cancer , cancer , oncology , medicine , cohort , stage (stratigraphy) , microrna , biology , biochemistry , paleontology , gene
MicroRNA (miRNA), which are stably present in serum, have been reported to be potentially useful for detecting cancer. In the present study, we examined the expression profiles of serum miRNA in several large cohorts to identify novel miRNA that can be used to detect early stage breast cancer. We comprehensively evaluated the serum miRNA expression profiles using highly sensitive microarray analysis. A total of 1280 serum samples of breast cancer patients stored in the National Cancer Center Biobank were used. In addition, 2836 serum samples were obtained from non‐cancer controls, 451 from patients with other types of cancers, and 63 from patients with non‐breast benign diseases. The samples were divided into a training cohort including non‐cancer controls, other cancers and breast cancer, and a test cohort including non‐cancer controls and breast cancer. The training cohort was used to identify a combination of miRNA that could detect breast cancer, and the test cohort was used to validate that combination. miRNA expressions were compared between patients with breast cancer and non‐breast cancer, and a combination of five miRNA (miR‐1246, miR‐1307‐3p, miR‐4634, miR‐6861‐5p and miR‐6875‐5p) was found to be able to detect breast cancer. This combination had a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% for breast cancer in the test cohort. In addition, this combination could detect early stage breast cancer (sensitivity of 98.0% for Tis).